Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Brady

Showing results (571-580 of 627) with videos related to

Pageof 63
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2019
Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group StudyJoan L Walker, Mark F Brady, Lari Wenzel, et al.
Journal of Medicinal Chemistry|August 14, 1998
Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 positionT J Tucker, S F Brady, W C Lumma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 3, 2024
Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005Jung-Min Lee, Mark F Brady, Austin Miller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 27, 2022
Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology StudyLarry J Copeland, Mark F Brady, Robert A Burger, et al.
Brain : a Journal of Neurology|June 6, 2018
Biallelic UFM1 and UFC1 mutations expand the essential role of ufmylation in brain developmentMichael S Nahorski, Sateesh Maddirevula, Ryosuke Ishimura, et al.
Lancet (London, England)|August 1, 2017
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)Krishnansu S Tewari, Michael W Sill, Richard T Penson, et al.
The Journal of Clinical Investigation|March 28, 2017
Somatic mutations and progressive monosomy modify SAMD9-related phenotypes in humansFederica Buonocore, Peter Kühnen, Jenifer P Suntharalingham, et al.
American Journal of Human Genetics|May 31, 2016
A Recurrent Mosaic Mutation in SMO, Encoding the Hedgehog Signal Transducer Smoothened, Is the Major Cause of Curry-Jones SyndromeStephen R F Twigg, Robert B Hufnagel, Kerry A Miller, et al.
The New England Journal of Medicine|November 14, 2019
Secondary Surgical Cytoreduction for Recurrent Ovarian CancerRobert L Coleman, Nick M Spirtos, Danielle Enserro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 19, 2022
Analysis of rare disruptive germline mutations in 2135 enriched BRCA-negative breast cancers excludes additional high-impact susceptibility genesC Loveday, A Garrett, P Law, et al.
Pageof 63

Showing results (571-580 of 627) with videos related to

Sort By:
Pageof 63
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2019
Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group StudyJoan L Walker, Mark F Brady, Lari Wenzel, et al.
Journal of Medicinal Chemistry|August 14, 1998
Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 positionT J Tucker, S F Brady, W C Lumma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 3, 2024
Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005Jung-Min Lee, Mark F Brady, Austin Miller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 27, 2022
Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology StudyLarry J Copeland, Mark F Brady, Robert A Burger, et al.
Brain : a Journal of Neurology|June 6, 2018
Biallelic UFM1 and UFC1 mutations expand the essential role of ufmylation in brain developmentMichael S Nahorski, Sateesh Maddirevula, Ryosuke Ishimura, et al.
Lancet (London, England)|August 1, 2017
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)Krishnansu S Tewari, Michael W Sill, Richard T Penson, et al.
The Journal of Clinical Investigation|March 28, 2017
Somatic mutations and progressive monosomy modify SAMD9-related phenotypes in humansFederica Buonocore, Peter Kühnen, Jenifer P Suntharalingham, et al.
American Journal of Human Genetics|May 31, 2016
A Recurrent Mosaic Mutation in SMO, Encoding the Hedgehog Signal Transducer Smoothened, Is the Major Cause of Curry-Jones SyndromeStephen R F Twigg, Robert B Hufnagel, Kerry A Miller, et al.
The New England Journal of Medicine|November 14, 2019
Secondary Surgical Cytoreduction for Recurrent Ovarian CancerRobert L Coleman, Nick M Spirtos, Danielle Enserro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 19, 2022
Analysis of rare disruptive germline mutations in 2135 enriched BRCA-negative breast cancers excludes additional high-impact susceptibility genesC Loveday, A Garrett, P Law, et al.
Pageof 63